Levulan (5-aminolevulinic acid) uptake. (DrugBank: Aminolevulinic acid, 5-Aminolevulinic acid)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
34 | Neurofibromatosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01682811 (ClinicalTrials.gov) | November 2011 | 5/9/2012 | Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) | Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light | Neurofibromatoses | Drug: Levulan (5-aminolevulinic acid) uptake.;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy. | Harry T Whelan, MD | NULL | Completed | 18 Years | 90 Years | All | 10 | Phase 1 | United States |